Novo Nordisk ready to roll with Russia plant; Teva, Novartis to unveil MS studies at neurology meeting;

@FiercePharma: North Carolina shuts down animal drug compounder. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Here's Baxter release on recall of 8 saline lots, 4 dextrose, 3 Lactated Ringer's Injection. Release | Follow @EricPFierce

> Novo Nordisk ($NVO) opened its new diabetes drug manufacturing plant in Russia, focusing on modern insulins in two types of injectors. Release

> Teva Pharmaceutical ($TEVA) is rolling out new data on its longer-acting formula of Copaxone at the American Academy of Neurology meeting this week. Release

> Novartis ($NVS) plans to unveil new data and analyses on its multiple sclerosis meds, including its blockbuster Gilenya pill, at the American Academy of Neurology meeting this week. Release

> Roche's ($RHHBY) anti-inflammatory drug Actemra is now under testing as a treatment for Type 1 diabetes. Report

> Mylan's ($MYL) proposed $29 billion buyout of Perrigo ($PRGO) could push its credit rating into junk territory if it's not careful about financing the deal with debt, analysts said. Report

> Novo Nordisk parent company Novo A/S tapped Bjarne Graven Larsen as its new CFO to replace the retiring Thorkil Christensen. Report

> Sales of medically important human antibiotics to the U.S. meat industry grew by 20% between 2009 and 2013, according to an FDA analysis. Report

Medical Device News

@FierceMedDev: FDA announces LuSys Labs' recall of its unapproved Ebola diagnostic. FierceDiagnostics article | Follow @FierceMedDev

@EmilyWFierce: NIH awards $11M to develop tests for drug-resistant bacteria. More from FierceDiagnostics | Follow @EmilyWFierce

> Qualcomm extends its Life2Net reach in deal with Cerner. Story

> ReCor Medical reels in $15M to recharge renal denervation efforts. Article

Biotech News

@FierceBiotech: Big Pharma partner: Check. Crossover round: Check. Hot tech: Check. IPO? Report | Follow @FierceBiotech

@JohnCFierce: Celgene buys into Mesoblast's stem cell pipeline in regenerative med pact. News | Follow @JohnCFierce

> After PhIII odyssey, the FDA finally gives Medicines Co a thumbs-up for cangrelor. Article

> FDA clears the way for Arrowhead's hep B treatment, with a caveat. Story

> Drew Fromkin takes the helm at Langer's Blend Therapeutics. Item

Animal Health News

> Zoetis innovation lab seeks to create electronic health record for every U.K. farm animal. Report

> Jennie-O-Turkey plant struck by bird flu. Story

> Mylan seeks entry into animal health via $29B bid for Perrigo. Item

> North Carolina shuts down animal drug compounder. Article

> Chicago outbreak of dog flu has authorities pitching Merck vaccine. More

Biotech IT News

> Rise of Big Data prompts peer review rethink at Nature Biotechnology. Item

> Early user of Venter's DNA synthesizer reports saving time, money. Report

> BioXcel adds Takeda to its roster of A-list clients. More

> Eisai's new research unit taps Genomics for analysis support. Story

> Peking University inks Medidata deal as China inches into eClinical era. Article

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.